Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 3, 1998, Pages 641-649

  Hicks, Kevin O ^b   Fleming, Yvette ^b   Siim, Bronwyn G ^b   Koch, Cameron J ^b   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NONE

Author keywords

Bioreductive drugs; EF5; Extravascular diffusion; Hypoxia; Multicellular layers; Tirapazamine

Indexed keywords

ACETAMIDE DERIVATIVE; CYTOTOXIC AGENT; OXYGEN; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CELL HYPOXIA; CELL STRAIN V 79; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG CYTOTOXICITY; DRUG DIFFUSION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TRANSPORT; EXTRAVASCULAR SPACE; HUMAN; HUMAN CELL; HUMAN TISSUE; MATHEMATICAL MODEL; MULTICELLULAR SPHEROID; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELLS, CULTURED; CRICETINAE; DIFFUSION; FIBROBLASTS; HUMANS; RADIATION-SENSITIZING AGENTS; SPHEROIDS, CELLULAR; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0031785201     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00268-5     Document Type: Article

References (34)

1. Bush RS, Jenkin RDT, Allt WEC, Beale FA, Bean H, Dembo AJ, Pringle JF. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37:302-306.
2. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-838.
3. Henk JM, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet 1977;104-105.
4. Hockel M, Knoop C, Schlenger K, Vorndran B, Baubmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
5. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39.
6. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
7. Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: The search for tumor specificity. Int J Radiat Oncol Biol Phys 1994;29:231-238.
8. Brown JM, Sum BG. Hypoxia specific cytotoxins in cancer therapy. Semin Radiat Oncol 1996;6:22-36.
9. Rockwell S. Use of hypoxia-directed drugs in therapy of solid tumors. Semin Oncol 1992;19:29-40.
10. Wilson WR. Tumour hypoxia: Challenges for cancer chemotherapy. In: Waring MJ, Ponder BAJ, editors. Cancer biology and medicine, vol. 3. Lancaster: Kluwer Academic Publishers; 1992. p. 87-131.
11. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J Natl Cancer Inst 1991;83: 178-185.
12. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 1991;20:457-461.
13. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-1242.
14. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50:7745-7749.
15. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-4636.
16. Dorie MJ, Brown JM. Modification of the antitumour activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 1997;39:361-366.
17. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 1997;5:213-219.
18. Olive PL. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. 1. Tirapazamine. Br J Cancer 1995;71:529-536.
19. Durand RE, Olive PL. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 1992;22: 689-692.
20. Cowan DSM, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer 1996;73(Suppl. 27):S28-S31.
21. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 1997;76:894-903.
22. Minchinton AI, Wendt KR, Clow KA, Fryer KH. Multilayers of cells growing on a permeable support - an in vitro tumour model. Acta Oncologica 1997;36:13-16.
23. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869-874.
24. Sum BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia. Cancer Res 1997;57:2922-2928.
25. Cussler EL. Diffusion, mass transfer in fluid systems. New York: Cambridge University Press; 1984.
26. Graham MA, Senan S, Robin HJ, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997;40:1-10.
27. Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, Vonroemeling R, Workman P, Kaye SB. Phase I and pharmacokinetic study of tirapazamine (sr 4233) administered every three weeks. Clin Cancer Res 1997;3:31-38.
28. Sum BG, van Zijl PL, Brown JM. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 1996;73:952-960.
29. Baker MA, Zeman EM, Hirst VK, Brown JM. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res 1988;48:5947-5952.
30. Subramaniam B, Claudius JS. Effect of intravenous drug administration mode on drug distribution in a tumor slab: A finite fourier transform analysis. J Theoret Biol 1990;143:55-76.
31. Kelson AB, McNamara JP, Pandey A, Ryan KJ, Dorie MJ, McAfee PA, Menke DR, Brown JM, Tracy M. 1,2,4-benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumour activity. Anticancer Drug Design; 1998; In press.
32. Wouters BG, Brown MJ. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-550.
33. Cliffe S, Taylor ML, Rutland M, Baguley B, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994; 29:373-377.
34. Delahoussaye YM, Wouters BG, Evans JE, Brown JM. The role of nuclear matrix-associated reductases in the activation of tirapazamine. 45th Annual Meeting, Radiation Research Soc: Abstract P05-112.1997.